
    
      Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative
      subjects and one cohort of HBeAg-positive subjects and 12 HbeAg-negative subjects will be
      enrolled in cohort 4. All subjects will be non-cirrhotic, with chronic hepatitis B virus
      (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with
      entecavir or tenofovir for at least 12 months.
    
  